Maria Pappa

Dr. Maria Pappa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VSVassilis Souliotis
Vassilis Souliotis
NVNikolaos I. Vlachogiannis
Nikolaos I. Vlachogiannis
MPMaria Pappa
Maria Pappa
AAAlexandra Argyriou
Alexandra Argyriou
PNPanagiotis A. Ntouros
Panagiotis A. Ntouros
PSPetros P. Sfikakis
Petros P. Sfikakis
The DNA damage response and repair (DDR/R) network, a sum of hierarchically structured signaling pathways that recognize and repair DNA damage, and the immune response to endogenous and/or exogenous threats, act synergistically to enhance cellular defense. On the other hand, a deregulated interplay between these systems underlines inflammatory diseases including malignancies and chronic systemic autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis. Patients with these diseases are characterized by aberrant immune response to self-antigens with widespread production of autoantibodies and multiple-tissue injury, as well as by the presence of increased oxidative stress. Recent data demonstrate accumulation of endogenous DNA damage in peripheral blood mononuclear cells from these patients, which is related to (a) augmented DNA damage formation, at least partly due to the induction of oxidative stress, and (b) epigenetically regulated functional abnormalities of fundamental DNA repair mechanisms. Because endogenous DNA damage accumulation has serious consequences for cellular health, including genomic instability and enhancement of an aberrant immune response, these results can be exploited for understanding pathogenesis and progression of systemic autoimmune diseases, as well as for the development of new treatments.

5 November 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
GFGeorge E. Fragoulis
George E. Fragoulis
VBVasiliki Kalliopi Bournia
Vasiliki Kalliopi Bournia
EMEugenia Mavrea
Eugenia Mavrea
GEGerasimos Evangelatos
Gerasimos Evangelatos
KFKalliopi Fragiadaki
Kalliopi Fragiadaki
PSPetros P. Sfikakis
Petros P. Sfikakis

Verified
Journal Article
Open access
PDF file
AMAthanasios Moustogiannis
Athanasios Moustogiannis
Anastassios PhilippouAnastassios Philippou
Anastassios Philippou
OTOrjona Taso
Orjona Taso
EZEvangelos Zevolis
Evangelos Zevolis
MPMaria Pappa
Maria Pappa
Michael KoutsilierisMichael Koutsilieris
Michael Koutsilieris
The process of myogenesis gradually deteriorates as the skeletal muscle ages, contributing to muscle mass loss. The aim of this study is to investigate the effect of senescence/aging on skeletal myogenesis, in vitro. A model of multiple cell divisions of C2C12 myoblasts was used to replicate cell senescence. Control and aged myoblasts were investigated during myogenesis, i.e., at days 0, 2, and 6of differentiation. SA-β-gal activity and comet assay were used as markers of aging and DNA damage. Flow cytometry was performed to characterize potential differences in cell cycle between control and aged cells. Alterations in the mRNA and/or protein expression of myogenic regulatory factors (MRFs), IGF-1 isoforms, apoptotic, atrophy, inflammatory, metabolic and aging-related factors were evaluated. Compared with the control cells, aged myoblasts exhibited G0/G1 cell cycle arrest, DNA damage, increased SA-β-gal activity, and increased expression of aging-related factors p16 and p21 during differentiation. Moreover, aged myoblasts showed a reduction in the expression of MRFs and metabolic/anabolic factors, along with an increased expression of apoptotic, atrophy and inflammatory factors. A diminished differentiation capacity characterized the aged myoblasts which, in combination with the induction of apoptotic and atrophy factors, indicated a disrupted myogenic lineage in the senescent muscle cells.

13 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
CCChristina Chatzi
Christina Chatzi
ABAthanasios Basios
Athanasios Basios
GMGeorgios Markozannes
Georgios Markozannes
ENEvangelia Ntzani
Evangelia Ntzani
KTKostas Tsilidis
Kostas Tsilidis
EREvangelos Rizos
Evangelos Rizos
Background/Objectives: Lifestyle interventions such as dietary changes have been proposed to control the cardiometabolic risk factors and thus prevent cardiovascular (CV) disease (CVD). We performed an umbrella review to investigate whether different dietary patterns affect CV risk in individuals with at least one cardiometabolic risk factor (hypertension, dyslipidemia, obesity, diabetes, metabolic syndrome) but not established CVD. Methods: We systematically searched the PubMed and Scopus databases (up to August 2024) for the systematic reviews and meta-analyses of randomized controlled trials (RCTs). Articles should be written in English and refer to a specific dietary pattern (such as Mediterranean diet, etc.). The population studied referred to adults with at least one cardiovascular (CV) risk factor. Results: From 4512 records identified, we finally included 25 meta-analyses with a total of 329 associations. Strong evidence for a benefit was found for LCD with reductions in BW [MD: −4.79 (95% CI −5.85, −3.72) kg, p ≤ 0.001], SBP [MD: −6.38 (95% CI −7.84, −4.93) mmHg, p ≤ 0.001], TG [WMD: −5.81 (95% CI −7.96, −3.66) mg/dL, p ≤ 0.001], and fasting plasma insulin [MD: −15.35 (95% CI −19.58, −11.12) pmol/L, p ≤ 0.001], as well as for low-GI diet for the reduction of BW [SMD: −0.66 (95% CI −0.90, −0.43) kg, p ≤ 0.001]. Conclusions: Across many dietary patterns, LCD showed strong or highly suggestive evidence for a benefit on SBP, BW reduction, and lipid profile improvement. Secondarily, low-GI, DASH, and Portfolio and Nordic diets suggested beneficial effects on controlling CV risk.

4 March 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
GFGeorge E. Fragoulis
George E. Fragoulis
IGIoannis Grigoropoulos
Ioannis Grigoropoulos
EMEvgenia Mavrea
Evgenia Mavrea
AAAikaterini Arida
Aikaterini Arida
VBVasiliki Kalliopi Bournia
Vasiliki Kalliopi Bournia
PSPetros P. Sfikakis
Petros P. Sfikakis

21 July 2023 in Current Rheumatology Reports
Verified
Journal Article
Open access
PDF file
MPMaria Pappa
Maria Pappa
APAlexandros Panagiotopoulos
Alexandros Panagiotopoulos
KTKonstantinos Thomas
Konstantinos Thomas
AFAntonis Fanouriakis
Antonis Fanouriakis
Purpose of Review: To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae. Recent Findings: Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Summary: Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications.